Core Insights - IMUNON, Inc. has withdrawn its Registration Statement on Form S-1 for a public offering, indicating a strategic shift in its funding approach [1] - The Registration Statement was initially filed on April 4, 2025, and has not been declared effective by the SEC, meaning no securities have been sold [1] Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body's natural mechanisms to address various human diseases [3] - The company is advancing its non-viral DNA technology, with two main modalities: TheraPlas for gene-based delivery of cytokines and PlaCCine for gene delivery of viral antigens [3] Clinical Programs - The lead clinical program, IMNN-001, is a DNA-based immunotherapy targeting advanced ovarian cancer, which has completed multiple clinical trials, including a Phase 2 trial [4] - IMNN-001 aims to instruct the body to produce cancer-fighting molecules at the tumor site, enhancing localized treatment effectiveness [4] - The company has also completed dosing in a first-in-human study of its COVID-19 booster vaccine, IMNN-101, and plans to continue advancing its technological capabilities [4]
IMUNON Announces Withdrawal of Form S-1 Registration Statement